Pfizer (BOM:500680) Cyclically Adjusted PB Ratio: (As of Sep. 03, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BOM:500680 Pfizer Ltd BOM:500680
75 GF Score
Price ₹4,627.15
GF Value ₹5,236.95
Valuation Modestly Undervalued
View Full Analysis

What is Pfizer Cyclically Adjusted PB Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Pfizer  (BOM:500680) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Pfizer Cyclically Adjusted PB Ratio Related Terms


Pfizer Cyclically Adjusted PB Ratio Historical Data

* Premium members only.

The historical data trend for Pfizer's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Pfizer Cyclically Adjusted PB Ratio Chart

Pfizer Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 6.60 5.09 5.86 5.20 5.77

Pfizer Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 6.30 0.00 5.77 0.00

BOM:500680 vs LLY, JNJ, ABBV: Cyclically Adjusted PB Ratio Comparison

For the Drug Manufacturers - General subindustry, Pfizer's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Pfizer Cyclically Adjusted PB Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Pfizer's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Pfizer's Cyclically Adjusted PB Ratio falls into.


BOM:500680
75GF Score
Pfizer Ltd BOM:500680
Cyclically Adjusted PB Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Pfizer Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Pfizer's Cyclically Adjusted Book per Share for the quarter that ended in Jun. 2026 is calculated as:

For example, Pfizer's adjusted Book Value per Share data for the three months ended in Jun. 2026 was:

Adj_Book=Book Value per Share/CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=0/167.3573*167.3573
=0.000

Current CPI (Jun. 2026) = 167.3573.

Pfizer Quarterly Data

Book Value per Share CPI Adj_Book
201609 499.805 105.961 789.403
201612 0.000 105.196 0.000
201703 528.740 105.196 841.177
201706 0.000 107.109 0.000
201709 542.168 109.021 832.275
201712 0.000 109.404 0.000
201803 586.517 109.786 894.081
201806 0.000 111.317 0.000
201809 604.606 115.142 878.787
201812 0.000 115.142 0.000
201903 658.245 118.202 931.981
201906 0.000 120.880 0.000
201909 689.884 123.175 937.342
201912 0.000 126.235 0.000
202003 742.216 124.705 996.072
202006 0.000 127.000 0.000
202009 468.228 130.118 602.234
202012 0.000 130.889 0.000
202103 523.092 131.771 664.362
202106 0.000 134.084 0.000
202109 564.381 135.847 695.292
202112 0.000 138.161 0.000
202203 626.128 138.822 754.832
202206 0.000 142.347 0.000
202209 637.453 144.661 737.464
202212 0.000 145.763 0.000
202303 701.080 146.865 798.905
202306 0.000 150.280 0.000
202309 715.439 151.492 790.365
202312 0.000 152.924 0.000
202403 785.945 153.035 859.503
202406 0.000 155.789 0.000
202409 819.898 157.882 869.103
202412 0.000 158.323 0.000
202503 921.879 157.552 979.254
202506 0.000 159.755 0.000
202509 841.193 162.289 867.462
202512 0.000 163.281 0.000
202603 918.707 164.272 935.960
202606 0.000 167.357 0.000

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

Is Pfizer (BOM:500680) Overvalued in 2026?

Based on GuruFocus' analysis, Pfizer stock appears to be undervalued. The current stock price of ₹4,627.15 is trading 11.6% below its estimated GF Value™ of ₹5,236.95. GuruFocus considers Pfizer to be Modestly Undervalued.

Key valuation signals for BOM:500680:

  • Cyclically Adjusted PB Ratio:
  • GF Value™: ₹5,236.95 vs. price of ₹4,627.15 (11.6% below fair value)
  • GF Score™: 75/100

No single metric tells the full story. See the BOM:500680 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Pfizer Business Description

Other Exchanges PFIZER:India
Address The Capital, 1802/1901, 18th Floor, Plot No. C - 70, G Block, Bandra Kurla Complex, Bandra (East), Mumbai, MH, IND, 400 051
Pfizer Ltd is engaged in manufacturing, marketing, trading and export of pharmaceutical products. The company has only one segment which is Pharmaceuticals and it operates in domestic market.
75GF Score

Get the complete analysis for BOM:500680

Cyclically Adjusted PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹4,627.15
Price
₹5,236.95
GF Value